Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
January 16, 2020
Hayden v. Portola Pharmaceuticals, Inc. et al
Case Number:
3:20-cv-00367
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Baker Botts
- Berman Tabacco
- Bernstein Litowitz
- Conrad Metlitzky
- DiCello Levitt
- Glancy Prongay
- Johnson & Johnson LLP
- K&L Gates
- Morrison Foerster
- Paul Weiss
- Robbins Geller
- Saxena White
Companies
- Citigroup Inc.
- Jackson Square Partners LLC
- Oppenheimer Holdings Inc.
- Portola Pharmaceuticals Inc.
- Southeastern Pennsylvania Transportation Authority
- The Goldman Sachs Group Inc.
- William Blair & Co. LLC
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
September 20, 2022
Portola Pharma Investors Ink $17.5M Deal Over Stock Declines
Investors in biotechnology company Portola Pharmaceuticals Inc. have asked a San Francisco federal judge to give an initial nod to a $17.5 million deal that would end claims the company failed to acknowledge its prime drug candidate, a blood coagulant, would face stiff competition from an off-label drug used for the same purpose, hurting investors when the company revealed its struggles to sell its drug.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login